Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

University of Melbourne

Status and phase: Enrolling; Phase 4

Conditions: Obesity; Knee Osteoarthritis; Osteoarthritis, Knee

Treatments: Drug: Tirzepatide; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06191848

75430

Details and patient eligibility

About

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.

Enrollment: 352 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a body mass index of ≥ 30 kg/m2.
• Report one or more previous unsuccessful attempt to lose body weight via lifestyle modification.
• Have been deemed eligible to enter the waiting list for primary knee replacement for the treatment of osteoarthritis in the target joint by an orthopaedic surgeon at one of the participating study sites.
• Have moderate-to-severe knee osteoarthritis in the target joint.
• Be willing to and capable of learning how to self-inject the study drug and follow study procedures for the duration of the trial.
• Provide informed consent to study participation in line with the requirements of the human research ethics committee of the study site.

Female participants must either:

• Not be of reproductive potential, defined as:

• Infertile due to surgical sterilization or congenital anomaly, OR

• Post-menopausal defined as:

  • A woman over the age of 40 years with spontaneous cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), with a follicle-stimulating hormone ≥40mIU/mL, and a negative pregnancy test prior to study entry, OR
  • A woman over the age of 55 years with cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), OR
  • A woman over the age of 55 years that has commenced hormone replacement therapy after a documented diagnosis of menopause.

OR

• Be of reproductive potential, and:

• Test negative for pregnancy on the initial screening visit via a serum pregnancy test, AND
• Use at least two effective forms of contraception, if sexually active, for the duration of the trial and until one month after the last injection of the study drug AND
• Not be breastfeeding.

Exclusion criteria

• Have been deemed eligible to enter the waiting list for knee replacement in the contralateral knee by an orthopaedic surgeon at one of the participating study sites.

• Have used any prescription medications intended to promote weight loss (e.g., tirzepatide, liraglutide, semaglutide) in the three months prior to screening.

• Have previously undergone any surgical or endoscopic procedure intended to promote weight loss.

• Have been diagnosed with type 1 diabetes mellitus (T1DM) or T2DM

• Have laboratory evidence indicative of diabetes mellitus during screening.

• Have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Have an active malignancy (excluding basal or squamous cell skin cancer).

• Have had a transplanted organ or awaiting an organ transplant

• Have evidence of a significant, active autoimmune abnormality (e.g., lupus or rheumatoid arthritis)

• Have any other medical conditions, abnormal laboratory tests or concomitant medications that make them unsuitable for participation:

  • Have a clinically significant gastric emptying abnormality.
  • Have had a history of acute or chronic pancreatitis.
  • Have obesity induced by other endocrinologic disorders
  • Have an unstable psychiatric disorder
  • Have uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)
  • Have had within the past 6 months prior to randomisation any of the following: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalisation due to congestive cardiac failure (are also exclusion criteria for elective knee replacement)
  • Have renal impairment as measured by a serum Creatinine of ≥0.3 mg/dL (≥26.5 μmol/L) at screening visit
  • Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 mIU/L at screening visit
  • Have acute or chronic hepatitis or abnormal liver function tests as measured by either alanine aminotransferase or alkaline phosphatase >200 IU.
  • Have a calcitonin level at Visit 1 of: ≥20 ng/L with eGFR ≥60 mL/min/1.73 m2, or ≥35 ng/L with eGFR <60 mL/min/1.73 m2.
  • Have any other known contraindication to any glucagon-like peptide-1 receptor agonists.

• Are study site personnel, or immediate family of a member of the study site.

• Have been enrolled in any other study of an investigational product within the past ninety days or are currently enrolled in such a study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

352 participants in 2 patient groups, including a placebo group

Tirzepatide

Experimental group

Description:

Drug: Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1receptor (GLP1R) agonist Dose: Tirzepatide will be initiated at 2.5mg once weekly, with the dose increasing by a further 2.5mg every four weeks until the target weekly dose of 15mg is achieved (or participants reach a lower maximum tolerated dose of 5mg or 10mg). Duration: 72-weeks Mode: subcutaneous

Treatment:

Drug: Tirzepatide

Placebo

Placebo Comparator group

Description:

Drug: Placebo Dose: once-weekly Duration: 72 weeks Mode: subcutaneous

Treatment:

Drug: Placebo